Literature DB >> 17826096

Hybrid approach for the design of highly affine and selective dopamine D(3) receptor ligands using privileged scaffolds of biogenic amine GPCR ligands.

Britta C Sasse1, Ulrich R Mach, Jukka Leppaenen, Thierry Calmels, Holger Stark.   

Abstract

A series of compounds containing privileged scaffolds of the known histamine H(1) receptor antagonists cetirizine, mianserin, ketotifen, loratadine, and bamipine were synthesized for further optimization as ligands for the related biogenic amine binding dopamine D(3) receptor. A pharmacological screening was carried out at dopamine D(2) and D(3) receptors. In the preliminary testing various ligands have shown moderate to high affinities for dopamine D(3)receptors, for example, N-(4-{4-[benzyl(phenyl)amino]piperidin-1-yl}butylnaphthalen-2-carboxamide (19a) (hD(3)K(i)=0.3 nM; hD(2)K(i)=703 nM), leading to a selectivity ratio of 2343.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17826096     DOI: 10.1016/j.bmc.2007.08.034

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Selectivity and activation of dopamine D3R from molecular dynamics.

Authors:  Zhiwei Feng; Tingjun Hou; Youyong Li
Journal:  J Mol Model       Date:  2012-07-03       Impact factor: 1.810

2.  Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy.

Authors:  Erin Milner; Jason Sousa; Brandon Pybus; Jennifer Auschwitz; Diana Caridha; Sean Gardner; Kristina Grauer; Erin Harris; Mark Hickman; Michael P Kozar; Patricia Lee; Susan Leed; Qigui Li; Victor Melendez; Jay Moon; Franklyn Ngundam; Michael O'Neil; Sandi Parriott; Brittney Potter; Rick Sciotti; Anchalee Tangteung; Geoffrey S Dow
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-03       Impact factor: 2.441

3.  Similarity maps - a visualization strategy for molecular fingerprints and machine-learning methods.

Authors:  Sereina Riniker; Gregory A Landrum
Journal:  J Cheminform       Date:  2013-09-24       Impact factor: 5.514

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.